During the past decade there has been a substantial advance in our understanding of
estrogen signaling both from a clinical as well as a preclinical perspective. Estrogen …

Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of
breast tumors express the estrogen receptor (ER). Tamoxifen and aromatase inhibitors (AIs) …

The 14-3-3 proteins were the first phosphoserine/phosphothreonine-binding proteins to be
discovered, a finding that provided the foundation for their prominent role in cell signaling …

Select changes in microRNA (miRNA) expression correlate with estrogen receptor α (ERα)
expression in breast tumors. miR-21 is higher in ERα positive than negative tumors, but no …

Tumor suppressor p53 maintains genome stability by regulating diverse cellular functions
including cell cycle arrest, apoptosis, senescence and metabolic homeostasis. Mutations in …

We used ChIP‐Seq to map ERα‐binding sites and to profile changes in RNA polymerase II
(RNAPII) occupancy in MCF‐7 cells in response to estradiol (E2), tamoxifen or fulvestrant …

Abstract YWHAZ (also named 14-3-3ζ) is a central hub protein for many signal transduction
pathways and plays a significant role in tumor progression. Accumulating evidences have …

An increased DNA repair capacity is associated with drug resistance and limits the efficacy
of chemotherapy in breast cancers. Flap endonuclease 1 (FEN1) participates in various …

By regulating activities and expression levels of key signaling molecules, estrogens control
mechanisms that are responsible for crucial cellular functions. Ligand binding to estrogen …

Many estrogen receptor (ER)-positive breast cancers respond well initially to endocrine
therapies, but often develop resistance during treatment with selective ER modulators …